Macrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesis

Current HIV Research

Volumn 12, Issue 2, 2014, Pages 111-120

  Rivera, Linda E ^a   Colón, Krystal ^a   Cantres Rosario, Yisel M ^a   Zenón, Frances M ^a   Meléndez, Loyda M ^a  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Cathepsin B; Cystatin B; Cystatin C; HAND; HIV 1; Macrophages

Indexed keywords

CATHEPSIN B; CYSTATIN B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT PROTEIN;

APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; DEGENERATIVE DISEASE; DIFFERENTIATION; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INNATE IMMUNITY; MACROPHAGE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; VIRUS REPLICATION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; METABOLISM; NERVOUS SYSTEM; PATHOPHYSIOLOGY; PHYSIOLOGY;

CATHEPSIN B; CYSTATIN B; FEMALE; HIV INFECTIONS; HUMANS; MACROPHAGES; MALE; NERVOUS SYSTEM; VIRUS REPLICATION;

EID: 84905669507     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X12666140526120249     Document Type: Article

References (110)

1. Turk V, Turk B, Guncar G, Turk D, Kos J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Advances in enzyme regulation. 2002; 42: 285-303.
2. Schwabe C, Anastasi A, Crow H. Cystatin. amino acid sequence and possible secondary structure. Biochem. J 1984; 217: 813-7.
3. Turk B, Turk D, Turk V. Lysosomal cysteine proteases: more than scavengers. Biochimica et biophysica acta 2000; 1477(1/2): 98-111.
4. Turk D, Podobnik M, Kuhelj R, Dolinar M, Turk V. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. FEBS letters 1996; 384(3): 211-4.
5. Sakamoto M, Miyamoto K, Wu Z, Nakanishi H. Possible involvement of cathepsin B released by microglia in methylmercury-induced cerebellar pathological changes in the adult rat. Neuroscience letters 2008; 442: 292-6.
6. Victor BC, Anbalagan A, Mohamed MM, Sloane BF, Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast cancer research: BCR. BioMed Central Ltd 2011; 13(6): R115.
7. Lackman RL, Jamieson AM, Griffith JM, Geuze H, Cresswell P. Innate immune recognition triggers secretion of lysosomal enzymes by macrophages. Traffic (Copenhagen, Denmark) 2007; 8(9):1179-89.
8. Katunuma N. Posttranslational processing and modification of cathepsins and cystatins. Journal of signal transduction 2010; 2010: 375345.
9. Lehtinen MK, Tegelberg S, Schipper H, Su H, Zukor H, Manninen O, et al. Cystatin B deficiency sensitizes neurons to oxidative stress in progressive myoclonus epilepsy, EPM1. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2009; 29(18):5910-5.
10. Luciano-Montalvo C, Ciborowski P, Duan F, Gendelman HE, Meléndez LM. Proteomic analyses associate cystatin B with restricted HIV-1 replication in placental macrophages. Placenta 2008; 29(12):1016-23.
11. Rivera-Rivera L, Perez-Laspiur J, Colón K, Meléndez LM. Inhibition of interferon response by cystatin B: implication in HIV replication of macrophage reservoirs. Journal of neurovirology 2012;18(1): 20-9.
12. Burgener A, Rahman S, Ahmad R, Lajoie J, Ramdahin S, Mesa C, et al. Comprehensive proteomic study identifies serpin and cystatin antiproteases as novel correlates of HIV-1 resistance in the cervicovaginal mucosa of female sex workers. Journal of proteome research 2011;10(11): 5139-49.
13. Lewin SR, Kirihara J, Sonza S, Irving L, Mills J, Crowe SM. HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. AIDS (London, England) 1998; 12(7): 719-27.
14. Bergamaschi A, Pancino G. Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology 2010; 7: 31.
15. Shen R, Richter HE, Clements RH, Novak L, Huff K, Bimczok D, et al. Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection. Journal of virology 2009; 83(7): 3258-67.
16. Naif HM, Li S, Alali M, Chang J, Mayne C, Sullivan J, et al. Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. Journal of virology. 1999; 73(6): 4866-81.
17. Hashimoto S, Suzuki T, Dong HY, Nagai S, Yamazaki N, Matsushima K. Serial analysis of gene expression in human monocyte-derived dendritic cells. Blood 1999; 94(3): 845-52.
18. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. Journal of leukocyte biology 2010; 87(4): 599-608.
19. Liu G, Yang H. Modulation of macrophage activation and programming in immunity. Journal of cellular physiology 2013; 228(3): 502-12.
20. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3(1): 23-35.
21. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends in immunology 2004; 25(12): 677-86.
22. Benoit M, Desnues B, Mege J-L. Macrophage polarization in bacterial infections. Journal of immunology (Baltimore, Md: 1950) 2008; 181(6): 3733-9.
23. Kopitar-Jerala N. The role of cystatins in cells of the immune system. FEBS letters 2006; 580(27): 6295-301.
24. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dc W, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE 2000; 2584-91.
25. Bol SM, Cobos-Jiménez V, Kootstra N, Van't Wout AB. HIV-1 and the macrophage. Future Virology 2011; 6(2):187-208.
26. Verdot L, Lalmanach G, Vercruysse V, Hartmann S, Lucius R, Hoebeke J, et al. Cystatins up-regulate nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages. The Journal of biological chemistry 1996; 271(45): 28077-81.
27. Verdot L, Lalmanach G, Vercruysse V, Hoebeke J, Gauthier F, Vray B. Chicken cystatin stimulates nitric oxide release from interferon-gamma-activated mouse peritoneal macrophages via cytokine synthesis. European journal of biochemistry/FEBS 1999; 266(3):1111-7.
28. Plaud-Valentin M, Delgado R, Garcia V, Zorrilla C, Gandia J, Meléndez-Guerrero LM. HIV infection of placental macrophages: effect on the secretion of HIV stimulatory cytokines. Cellular and molecular biology (Noisy-le-Grand, France) 1999; 45(4): 423-31.
29. García K, García V, Pérez Laspiur J, Duan F, Meléndez LM. Characterization of the placental macrophage secretome: implications for antiviral activity. Placenta 2009; 30(2):149-55.
30. Ciborowski P, Kadiu I, Rozek W, Smith L, Bernhardt K, Fladseth M, et al. Investigating the human immunodeficiency virus type 1-infected monocyte-derived macrophage secretome. Virology 2007; 363(1):198-209.
31. Rodriguez-Franco EJ, Cantres-Rosario YM, Plaud-Valentin M, Romeu R, Rodríguez Y, Skolasky R, et al. Dysregulation of macrophage-secreted cathepsin B contributes to HIV-1-linked neuronal apoptosis. PloS one 2012; 7(5): e36571.
32. Luciano-Montalvo C, Meléndez LM. Cystatin B associates with signal transducer and activator of transcription 1 in monocyte-derived and placental macrophages. Placenta. Elsevier Ltd 2009; 30(5): 464-7.
33. Magnani M, Balestra E, Fraternale A, Aquaro S, Paiardini M, Cervasi B, et al. Drug-loaded red blood cell-mediated clearance of HIV-1 macrophage reservoir by selective inhibition of STAT1 expression. Journal of leukocyte biology 2003; 74(5):764-71.
34. Chang T, Mosoian A, Pine R. A Soluble Factor (s) Secreted from CD8 T Lymphocytes Inhibits Human Immunodeficiency Virus Type 1 Replication through STAT1 Activation. Journal of 2002; 76(2): 569-81.
35. Meléndez J, García V, Sánchez E, Delgado R, Torres G, Meléndez-Guerrero LM. Is decreased HIV-1 infectivity of placental macrophages caused by high levels of beta-chemokines? Cellular and molecular biology (Noisy-le-Grand, France) 2001; 47 Online: OL51-9.
36. Chaudhuri A, Duan F, Morsey B, Persidsky Y, Kanmogne GD. HIV-1 activates proinflammatory and interferon-inducible genes in human brain microvascular endothelial cells: putative mechanisms of blood-brain barrier dysfunction. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 2008; 28(4): 697-711.
37. Asin S, Taylor JA, Trushin S, Bren G, Paya C V. I kappa kappa Mediates NF-kappa Beta Activation in Human Immunodeficiency Virus-Infected Cells. J Virol 1999; 73(5): 3893-903.
38. McElhinny J, MacMorran WS, Bren GD, Ten RM, Israela, Paya CV. Regulation of I kappa B alpha and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus. Journal of virology 1995; 69(3):1500-9.
39. Kadiu I, Wang T, Schlautman JD, Dubrovsky L, Ciborowski P, Bukrinsky M, et al. HIV-1 transforms the monocyte plasma membrane proteome. Cellular immunology. Elsevier Inc 2009; 258(1): 44-58.
40. Cantres-Rosario Y, Plaud-Valentín M, Gerena Y, Skolasky RL, Wojna V, Meléndez LM. Cathepsin B and cystatin B in HIV-seropositive women are associated with infection and HIV-1-associated neurocognitive disorders. AIDS (London, England) 2013; 27(3):347-56.
41. Ha S-D, Park S, Hattlmann CJ, Barr SD, Kim SO. Inhibition or deficiency of cathepsin B leads defects in HIV-1 Gag pseudoparticle release in macrophages and HEK293T cells. Antiviral research. Elsevier B.V 2012; 93(1):175-84.
42. Yoshii H, Kamiyama H, Goto K, Oishi K, Katunuma N, Tanaka Y, et al. CD4-independent human immunodeficiency virus infection involves participation of endocytosis and cathepsin B. PloS one 2011; 6(4): e19352.
43. Kubo Y, Hayashi H, Matsuyama T, Sato H, Yamamoto N. Retrovirus entry by endocytosis and cathepsin proteases. Advances in virology 2012; 2012: 640894.
44. Laforge M, Petit F, Estaquier J, Senik A. Commitment to apoptosis in CD4(+) T lymphocytes productively infected with human immunodeficiency virus type 1 is initiated by lysosomal membrane permeabilization, itself induced by the isolated expression of the viral protein Nef. Journal of virology 2007; 81(20):11426-40.
45. Zavasnik-Bergant T. Cystatin protease inhibitors and immune functions. Frontiers in bioscience: a journal and virtual library 2008; 13: 4625-37.
46. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biological chemistry 2007; 388(11):1141-9.
47. Magister S, Kos J. Cystatins in immune system. Journal of Cancer 2013;4(1): 45-56.
48. Ceru S, Layfield R, Zavasnik-Bergant T, Repnik U, Kopitar-Jerala N, Turk V, et al. Intracellular aggregation of human stefin B: confocal and electron microscopy study. Biology of the cell/under the auspices of the European Cell Biology Organization 2010; 102(6): 319-34.
49. Skerget K, Taler-Vercic A, Bavdek A, Hodnik V, Ceru S, Tusek-Znidaric M, et al. Interaction between oligomers of stefin B and amyloid-beta in vitro and in cells. The Journal of biological chemistry 2010; 285(5): 3201-10.
50. Hook V, Funkelstein L, Wegrzyn J, Bark S, Kindy M, Hook G. Cysteine Cathepsins in the secretory vesicle produce active peptides: Cathepsin L generates peptide neurotransmitters and cathepsin B produces beta-amyloid of Alzheimer's disease. Biochimica et Biophysica Acta. Elsevier B.V 2012;1824(1): 89-104.
51. Hook VYH, Toneff T, Aaron W, Yasothornsrikul S, Bundey R, Reisine T. Beta-amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for beta-secretase activity in chromaffin vesicles. Journal of neurochemistry 2002; 81(2): 237-56.
52. Hook V, Toneff T, Bogyo M, Greenbaum D, Medzihradszky KF, Neveu J, et al. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate beta-secretase of Alzheimer's disease. Biological chemistry 2005; 386(9): 931-40.
53. Hook VYH, Kindy M, Reinheckel T, Peters C, Hook G. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochemical and biophysical research communications 2009; 386(2): 284-8.
54. Hook V, Hook G, Kindy M. Pharmacogenetic features of cathepsin B inhibitors that improve memory deficit and reduce beta-amyloid related to Alzheimer's disease. Biological chemistry 2010; 391(8): 861-72.
55. Hook G, Hook V, Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity. Journal of Alzheimer's disease: JAD 2011; 26(2): 387-408.
56. Kindy MS, Yu J, Zhu H, El-Amouri SS, Hook V, Hook GR. Deletion of the cathepsin B gene improves memory deficits in a transgenic ALZHeimer's disease mouse model expressing AβPP containing the wild-type β-secretase site sequence. Journal of Alzheimer's disease: JAD 2012; 29(4): 827-40.
57. Bahr B a, Wisniewski ML, Butler D. Positive lysosomal modulation as a unique strategy to treat age-related protein accumulation diseases. Rejuvenation research 2012;15(2):189-97.
58. Butler D, Hwang J, Estick C, Nishiyama A, Kumar SS, Baveghems C, et al. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PloS one 2011; 6(6): e20501.
59. Wang C, Sun B, Zhou Y, Grubb A, Gan L. Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein. The Journal of biological chemistry 2012; 287(47): 39834-41.
60. Oh JE, Lee HK. Autophagy as an innate immune modulator. Immune network. 2013;13(1):1-9.
61. Tatti M, Motta M, Di Bartolomeo S, Scarpa S, Cianfanelli V, Cecconi F, et al. Reduced cathepsins B and D cause impaired autophagic degradation that can be almost completely restored by overexpression of these two proteases in Sap C-deficient fibroblasts. Human molecular genetics 2012; 21(23): 5159-73.
62. Haves-Zburof D, Paperna T, Gour-Lavie A, Mandel I, Glass-Marmor L, Miller A. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. Journal of cellular and molecular medicine 2011;15(11): 2421-9.
63. Bever CT, Garver DW. Increased cathepsin B activity in multiple sclerosis brain. Journal of the neurological sciences0 1995;131(1): 71-3.
64. Bever CT, Panitch HS, Johnson KP. Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients. Neurology 1994; 44(4): 745-8.
65. Luo C-L, Chen X-P, Yang R, Sun Y-X, Li Q-Q, Bao H-J, et al. Cathepsin B contributes to traumatic brain injury-induced cell death through a mitochondria-mediated apoptotic pathway. Journal of neuroscience research 2010; 88(13): 2847-58.
66. Zhang Y, Chen X, Tao L, Qin Z, Li S, Yang L, et al. Expression of cathepsin-B and -D in rat's brain after traumatic brain injury. Fa Yi Xue Za Zhi 2006; 22(6): 404-406.
67. Rao Malla R, Gopinath S, Alapati K, Gorantla B, Gondi CS, Rao JS. Knockdown of cathepsin B and uPAR inhibits CD151 and α3β1 integrin-mediated cell adhesion and invasion in glioma. Molecular carcinogenesis 2012; (November 2011): 1-14.
68. Spudich SS, Ances BM. Neurologic complications of HIV infection. Topics in antiviral medicine 2012; 20(2): 41-7.
69. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central nervous system viral invasion and inflammation during acute HIV infection. The Journal of infectious diseases 2012; 206(2): 275-82.
70. Spudich S, González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harbor perspectives in medicine 2012; 2(6): a007120.
71. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science (New York, N.Y.) 1986; 233(4768):1089-93.
72. Masliah E, Achim CL, Hansen LA, Wiley CA. Selective neuronal vulnerability in HIV encephalitis. Journal of neuropathology and experimental neurology 1992; 51(6): 585-93.
73. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu XJ, Stins M, et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. The American journal of pathology 1999;155(5):1599-611.
74. Reddy PVB, Gandhi N, Samikkannu T, Saiyed Z, Agudelo M, Yndart A, et al. HIV-1 gp120 induces antioxidant response element-mediated expression in primary astrocytes: Role in HIV associated neurocognitive disorder. Neurochemistry international. Elsevier B.V 2011;1-8.
75. Williams KC, Corey S, Westmoreland S V, Pauley D, Knight H, deBakker C, et al. Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. The Journal of experimental medicine 2001;193(8): 905-15.
76. Yang B, Akhter S, Chaudhuri A, Kanmogne GD. HIV-1 gp120 induces cytokine expression, leukocyte adhesion, and transmigration across the blood-brain barrier: modulatory effects of STAT1 signaling. Microvascular research. Elsevier Inc 2009; 77(2): 212-9.
77. Agrawal L, Louboutin J-P, Reyes B a S, Van Bockstaele EJ, Strayer DS. HIV-1 Tat neurotoxicity: a model of acute and chronic exposure, and neuroprotection by gene delivery of antioxidant enzymes. Neurobiology of disease. Elsevier Inc 2012; 45(2): 657-70.
78. Eugenin E, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tat-induced apoptosis. Journal of Neurochemistry 2003; 85(5): 1299-311.
79. Van Marle G, Henry S, Todoruk T, Sullivan A, Silva C, Rourke SB, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004; 329(2): 302-18.
80. Hui L, Chen X, Haughey NJ, Geiger JD. Role of endolysosomes in HIV-1 Tat-induced neurotoxicity. ASN neuro 2012; 4(4): 243-52.
81. Louboutin J-P, Agrawal L, Reyes B a S, Van Bockstaele EJ, Strayer DS. HIV-1 gp120 neurotoxicity proximally and at a distance from the point of exposure: protection by rSV40 delivery of antioxidant enzymes. Neurobiology of disease. Elsevier Inc 2009; 34(3): 462-76.
82. Johansson A-C, Appelqvist H, Nilsson C, Kågedal K, Roberg K, Ollinger K. Regulation of apoptosis-associated lysosomal membrane permeabilization. Apoptosis: an international journal on programmed cell death 2010;15(5): 527-40.
83. Oberle C, Huai J, Reinheckel T, Tacke M, Rassner M, Ekert PG, et al. Lysosomal membrane permeabilization and cathepsin release is a Bax/Bak-dependent, amplifying event of apoptosis in fibroblasts and monocytes. Cell death and differentiation. Nature Publishing Group 2010;17(7):1167-78.
84. Droga-Mazovec G, Bojic L, Petelin A, Ivanova S, Romih R, Repnik U, et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. The Journal of biological chemistry 2008; 283(27):19140-50.
85. Yamashima T, Oikawa S. The role of lysosomal rupture in neuronal death. Progress in neurobiology 2009; 89(4): 343-58.
86. Gelman BB, Wolf D, Rodriguez-Wolf M, West a B, Haque a K, Cloyd M. Mononuclear phagocyte hydrolytic enzyme activity associated with cerebral HIV-1 infection. The American journal of pathology 1997; 151(5):1437-46.
87. Murphy N, Lynch M a. Activation of the P2X7 receptor induces migration of glial cells by inducing cathepsin B degradation of tissue inhibitor of metalloproteinase 1. Journal of neurochemistry 2012;123(5):761-70.
88. Koch S, Scifo E, Rokka A, Trippner P, Lindfors M, Korhonen R, et al. Cathepsin D deficiency induces cytoskeletal changes and affects cell migration pathways in the brain. Neurobiology of disease Elsevier Inc 2013; 50:107-19.
89. Suresh DR, Annam V, Pratibha K, Prasad BVM. Total antioxidant capacity--a novel early bio-chemical marker of oxidative stress in HIV infected individuals. Journal of biomedical science 2009;16:61.
90. Sacktor N, Haughey N, Cutler R, Tamara A, Turchan J, Pardo C, et al. Novel markers of oxidative stress in actively progressive HIV dementia. Journal of neuroimmunology 2004;157(1/2):176-84.
91. Viviani B, Corsini E, Binaglia M, Galli CL, Marinovich M. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 2001;107(1):51-8.
92. Aquaro S, Scopelliti F, Pollicita M, Perno CF. Oxidative stress and HIV infection: target pathways for novel therapies? Future HIV Therapy 2008; 2(4): 327-38.
93. Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. Journal of virology 1989; 63(10): 4404-8.
94. Morris D, Guerra C, Donohue C, Oh H, Khurasany M, Venketaraman V. Unveiling the mechanisms for decreased glutathione in individuals with HIV infection. Clinical & developmental immunology 2012; 2012: 734125.
95. Pyo C-W, Yang YL, Yoo N-K, Choi S-Y. Reactive oxygen species activate HIV long terminal repeat via post-translational control of NF-kappaB. Biochemical and biophysical research communications 2008; 376(1):180-5.
96. Kraft-Terry S, Gerena Y, Wojna V, Plaud-Valentin M, Rodriguez Y, Ciborowski P, et al. Proteomic analyses of monocytes obtained from Hispanic women with HIV-associated dementia show depressed antioxidants. Proteomics. Clinical applications 2010; 4(8/9): 706-14.
97. Velázquez I, Plaud M, Wojna V, Skolasky R, Laspiur JP, Meléndez LM. Antioxidant enzyme dysfunction in monocytes and CSF of Hispanic women with HIV-associated cognitive impairment. Journal of neuroimmunology 2009; 206(1/2):106-11.
98. Toro-Nieves DM, Rodriguez Y, Plaud M, Ciborowski P, Duan F, Pérez Laspiur J, et al. Proteomic analyses of monocyte-derived macrophages infected with human immunodeficiency virus type 1 primary isolates from Hispanic women with and without cognitive impairment. Journal of neurovirology 2009;15(1): 36-50.
99. Polajnar M, Ceru S, Kopitar-Jerala N, Zerovnik E. Human stefin B normal and patho-physiological role: molecular and cellular aspects of amyloid-type aggregation of certain EPM1 mutants. Frontiers in molecular neuroscience 2012; 5: 88.
100. Owens J. Determining druggability. Nature Reviews Drug Discovery 2007; 6(3):187-187.
101. Frlan R, Gobec S. Inhibitors of cathepsin B. Current medicinal chemistry 2006;13(19): 2309-27.
102. Yamashima T, Kohda Y, Tsuchiya K, Ueno T, Yamashita J, Yoshioka T, et al. Inhibition of ischaemic hippocampal neuronal death in primates with cathepsin B inhibitor CA-074: a novel strategy for neuroprotection based on "calpain-cathepsin hypothesis". The European journal of neuroscience 1998; 10(5):1723-33.
103. Sharma S, Singh A. Nanotechnology Based Targeted Drug Delivery: Current Status and Future Prospects for Drug Development 2007;
104. Could N, Cancer R. Nanomedicine Could Revolutionize Cancer, HIV Research 2010;12-4.
105. Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (London, England) 2010; 5(2): 269-85.
106. Kim PS, Read SW. Nanotechnology and HIV: potential applications for treatment and prevention. Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2010; 2(6): 693-702.
107. Ganau M, Prisco L, Pescador D, Ganau L. Challenging New Targets for CNS-HIV Infection. Frontiers in neurology 2012; 3:43.
108. Paperna T, Mandel I, Miller A. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis 1-2.
109. Conus S, Simon H-U. Cathepsins and their involvement in immune responses. Swiss medical weekly 2010; 140(July): w13042.
110. Reiser J, Adair B, Reinheckel T. Science in medicine Specialized roles for cysteine cathepsins in health and disease 2010; 120(10): 24-6.